Meningococcal Vaccines Market Report 2026

Meningococcal Vaccines Market Overview

• Meningococcal Vaccines market size has reached to $4.26 billion in 2025 • Expected to grow to $6.58 billion in 2030 at a compound annual growth rate (CAGR) of 9.1% • Growth Driver: Impact Of Rising Healthcare Spending On Meningococcal Vaccines • Market Trend: Pfizer's Comprehensive Meningococcal Vaccine With FDA Approval • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Meningococcal Vaccines Market?

Meningococcal vaccinations are vaccines that protect against Neisseria meningitidis, the bacteria responsible for meningitis and bloodstream infections. These vaccines help the immune system recognize and fight the bacteria before it causes illness. These are used to prevent severe, potentially life-threatening meningococcal disease, especially in high-risk groups such as adolescents, college students, and travelers. The main types of meningococcal vaccines are meningococcal conjugate vaccine, polysaccharide vaccine, and subcapsular vaccine. Meningococcal conjugate vaccine refers to a compound made up of a polysaccharide antigen fused (conjugated) to a carrier molecule. The different serotypes include Men ACWY, Men B/Bc, and Men C, given to various age groups such as infants, children, adolescents, young adults, and adults, and distributed by pharmacies, community clinics, public health agencies, and others. These are used by various end-users, such as hospitals, research institutions, and academic institutes.

What Is The Meningococcal Vaccines Market Growth Forecast?

The meningococcal vaccines market size is expected to see strong growth in the next few years. It will grow to $6.58 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to advancements in vaccine technology, expansion of global immunization programs, increasing awareness of meningococcal disease, strategic partnerships and collaborations, growth in adolescent and young adult vaccination initiatives. Major trends in the forecast period include expansion of pediatric vaccination programs, development of broad-spectrum meningococcal vaccines, increased government immunization initiatives, rising awareness of meningococcal disease prevention, growth of school and college vaccination campaigns.

What Is The Driver Of The Meningococcal Vaccines Market?

An increase in healthcare spending is expected to propel the growth of the meningococcal vaccine market going forward. Healthcare refers to a residential care institution, nursing facility, intermediate care facility for people with mental illnesses, or intermediate care facility for people with mental retardation. The high expense of new vaccine generations compared to their predecessors has become a key factor in discussions about whether the benefits of the new vaccinations justify their prices. Assessing the complete social and economic advantages of vaccination is becoming an increasingly important area of investigation in the literature on valuing vaccination. For instance, in April 2025, according to an article published by the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, Health spending in the U.S. increased by 7.5% in 2023 to $4.9 trillion or $14,570 per capita. This growth rate is significantly higher than the 4.6% rise in 2022. Therefore, an increase in healthcare spending is driving the growth of the meningococcal vaccine industry.

Key Players In The Global Meningococcal Vaccines Market

Major companies operating in the meningococcal vaccines market are Pfizer Inc.,GlaxoSmithKline plc,Sanofi Pasteur,Merck & Co. Inc.,Serum Institute of India Pvt. Ltd.,Bio-Manguinhos,Walvax Biotechnology Co. Ltd.,Bharat Biotech,Panacea Biotec Ltd.,CSL Limited,Minhai Biotechnology Co. Ltd.,Hualan Biological Engineering Inc.,Shenzhen Kangtai Biological Products Co. Ltd.,Chongqing Zhifei Biological Products Co. Ltd.,Incepta Pharmaceuticals Ltd.,Biological E. Limited,Biokangtai,Biomed Pvt Ltd.,Biocine SCL,Bavarian Nordic A/S

Global Meningococcal Vaccines Market Trends and Insights

Major companies operating in the meningococcal vaccines market are developing new vaccines for the prevention of serogroups to increase their profitability in the market. Meningococcal vaccines are preventive measures designed to protect individuals against infections caused by specific serogroups of the bacteria Neisseria meningitidis. For instance, in October 2023, Pfizer Inc., a US-based pharmaceutical company received approval from FDA for the vaccine PENBRAYA. PENBRAYA, with extensive serogroup coverage, is the most comprehensive U.S.-approved meningococcal vaccine, safeguarding against groups A, B, C, W, and Y. FDA approval is grounded in robust Phase 2 and 3 trial data, confirming non-inferior immunogenicity to Trumenba + Menveo across all serogroups, coupled with favorable safety. Pfizer's September 2022 announcement revealed positive outcomes from a Phase 3 trial, comparing PENBRAYA to existing licensed meningococcal vaccines in terms of safety, tolerability, and immunogenicity.

What Are Latest Mergers And Acquisitions In The Meningococcal Vaccines Market?

In September 2023, Biovac Institute, a South Africa-based vaccine manufacturer, formed a partnership with EuBiologics Co., Ltd, to facilitate the technology transfer of meningitis vaccines. The collaboration aims to enhance local production capabilities, improve access to high-quality meningitis vaccines, and strengthen regional immunization programs while fostering innovation and growth in vaccine development. EuBiologics Co., Ltd is a South Korea-based biopharmaceutical company specializes in the research, development, and commercialization of vaccines for infectious diseases.

What Defines the Meningococcal Vaccines Market?

The meningococcal vaccines market consists of sales of conjugate vaccines, combination vaccines, serogroup B vaccine products, and other types. Values in this market are ‘pharmaceuticals’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Meningococcal Vaccines Market Report 2026?

The meningococcal vaccines market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the meningococcal vaccines industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.